The LWP is devoted to advancing research and promoting education regarding the role of stem cell transplantation in the management of patients with lymphoid malignancies.
The LWP is composed of a panel of experts on Hodgkin lymphoma and non Hodgkin lymphoma, including diffuse large B-cell lymphoma, T-cell lymphomas, mantle cell lymphoma, follicular lymphoma and Waldenström macroglobulinemia. The panel is supported by the excellent help of Hervé Finel and Irma Khvedelidze, Study Coordinators, and Ariane Boumendil, Statistician.
The joint effort of the team has resulted in a very active portfolio of ongoing studies and numerous presentations in international meetings and publications in peer-reviewed journals. This includes both retrospective and prospective studies, as well as guidelines and position papers.
Follow us on Twitter @LymphomaWP_EBMT
Learn more about the LWP
The management of patients with lymphoma has changed extraordinarily in the last 10-15 years. The advent of rituximab has resulted in a significant improvement in the outcome of several types of lymphoma. More recently, a plethora of new agents with a very strong biological rational is becoming available for the treatment of patients with lymphoid malignancies. In parallel, advances in haematopoietic cell transplantation technology, such as reduced toxicity conditioning, haplo-transplantation, and CAR T cell therapy have improved the outcome and widened the applicability of stem cell transplantation in lymphoma, particularly for elderly patients and those without a matched donor.
The challenge is to continuously define the appropriate place for stem cell transplant in the therapeutic algorithm of patients with lymphoma in concert with the novel pharmacological options. With the largest database of patients that have undergone a stem cell transplant for lymphoma combined with the expertise of the transplant community, the LWP is in a privileged position to contribute to this aim.
To submit a proposal to the LWP for a new study, download the following document:
LWP Publications List
Guidelines, Consensus Statements, and Position Papers
Open calls to participate in a new study
The Lymphoma Working Party is currently overseeing the following studies with open calls for participation.
Long Term Outcome of a Second Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma: A Retrospective Analysis from the Lymphoma Working Party of EBMT
Open until: ongoing
Please contact the Study Coordinators if you are interested in participating.
Checkpoint inhibition for treating Hodgkin and Non-Hodgkin lymphoma in the context of allogeneic stem cell transplantation: A survey-based registry study of the EBMT Lymphoma Working Party
Open until: ongoing
This study aims to investigate safety and efficacy of immune checkpoint inhibitor treatment before and after allogeneic stem cell transplantation in NHL and HL.
Main objectives of the study are to investigate if:
- checkpoint blockade pre-treatment might influence the outcome of a subsequent allo-HSCT
- post-transplant checkpoint blockade for treatment of lymphoma relapse is safe and effective
- Patients who received an allo-HSCT after January 2014
- Documented pre or post-transplant exposure to Immune checkpoint inhibitors
- Diagnosis of NHL or HL
- Age over 18 years at transplant
- Donor: SIB, UD, haplo-identical donor, cord blood donor
- Any conditioning regimen